Andrea Ruth Hagemann MD
Gynecologic Oncology
Gynecologic Oncology
Join to View Full Profile
4921 Parkview Pl# DvSt. Louis, MO 63110
Phone+1 314-362-3181
Fax+1 314-362-2893
Dr. Hagemann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Pennsylvania Health SystemFellowship, Gynecologic Oncology, 2008 - 2011
Washington University/B-JH/SLCH ConsortiumResidency, Obstetrics and Gynecology, 2004 - 2008- Washington University in St. Louis School of MedicineClass of 2004
Certifications & Licensure
IL State Medical License 2020 - 2026
MO State Medical License 2011 - 2026
PA State Medical License 2008 - 2012
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients Start of enrollment: 2010 Aug 01
- Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma Start of enrollment: 2016 Jan 01
- Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome Start of enrollment: 2021 Apr 09
Publications & Presentations
PubMed
- Targeting RAD52 overcomes PARP inhibitor resistance in preclinical-deficient ovarian cancer model.Yukihide Ota, Vijayalaxmi Gupta, Bisiayo E Fashemi, Moreniola Akande, Preedia Babu
Biorxiv. 2025-09-26 - Population-Level Reduction in Ovarian Cancer Through Performance of Opportunistic Salpingectomy at the Time of Cholecystectomy.Jason D Wright, Ling Chen, Carly Tymm, Xiao Xu, Jennifer S Ferris
Annals of Surgery. 2025-09-15 - Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy-Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response.Mark C Valentine, Mary M Mullen, Emilee N Kotnik, Matthew A Powell, Premal H Thaker
Cancer Research. 2025-09-15
Journal Articles
- Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian CancerIan S Hagemann, Premal H Thaker, Carolyn K McCourt, Katherine C Fuh, David G Mutch, Andrea R Hagemann, Matthew A Powell, Clinical Cancer Research
- Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous CancerIan S Hagemann, Carolyn K McCourt, Matthew A Powell, Premal H Thaker, David G Mutch, Katherine C Fuh, Andrea R Hagemann, Clinical Cancer Research
Press Mentions
Medical Students Celebrate Their Teachers, MentorsNovember 19th, 2019
Case Series Do Gynecologic Oncology Patients with Severely Diminished Renal Function and Urinary Tract Obstruction Benefit from Ureteral Stenting or Percutaneous Nephrostomy?May 12th, 2019
$11.6 Million Grant Supports Innovative Research in Endometrial Cancer – Washington University School of Medicine in St. LouisSeptember 7th, 2023- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
